AveXis publishes new information to global Managed Access Program (MAP)

The global Managed Access Program (MAP) for Zolgensma® (onasemnogene abeparvovec) was already heavily debated. Some countries welcomed them, other countries were quite outraged by the selection process.

In the meantime Zolgensma is approved in Europe by the EMA. The respective countries have to decide whether approval in their country.

Okay, where people work, mistakes are made. AveXis says apologize and followed the feedback from the SMA community.

Read more below!